Persius/hicric huggingface dataset:
Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101.
The rules say that High frequency chest wall oscillation devices (HFCWO) (E0483) are covered for beneficiaries who meet:
A. Criterion 1, 2, or 3, and
B. Criterion 4
1. There is a diagnosis of cystic fibrosis.
2. There is a diagnosis of bronchiectasis which has been confirmed by a high resolution, spiral, or standard CT scan and which is characterized by:
a.
a. Daily productive cough for at least 6 continuous months; or
b. Frequent (i.e., more than 2/year) exacerbations requiring antibiotic therapy.
Chronic bronchitis and chronic obstructive pulmonary disease (COPD) in the absence of a confirmed diagnosis of bronchiectasis do not meet this criterion.
3. The beneficiary has one of the following neuromuscular disease diagnoses: Post-polio Acid maltase deficiency Anterior horn cell diseases Multiple sclerosis Quadriplegia Hereditary muscular dystrophy Myotonic disorders Other myopathies Paralysis of the diaphragm
4. There must be well-documented failure of standard treatments to adequately mobilize retained secretions.
If all of the criteria are not met, the claim will be denied as not reasonable and necessary. You can find this rule in the Local Coverage Determination for High Frequency Chest Wall Oscillation Devices, L33785 (eff 01/01/20).
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com.
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that to qualify for portable oxygen, the patient must meet the criteria for home oxygen. The 
documentation must show that the patient is mobile in the home and would benefit from the use of portable 
oxygen in the home. Portable oxygen is not covered for patients who qualify for oxygen solely based on blood 
gas studies obtained during sleep. You can find this rule in the Medicare National Coverage Determinations 
Manual, Section 240.2(E).  
 
For patients with arterial PO2 at or above 60 mm Hg or arterial O2 saturation at or above 90% on room air, 
there is a rebuttable presumption of non-coverage. You can find this rule in the Medicare National Coverage 
Determinations Manual, Section 240.2(D)(3). 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101.
The rules say that tumor treatment field therapy (E0766) is covered for the treatment of newly diagnosed Glioblastoma Multiforme (GBM) only when all of the following criteria are met:
1. The beneficiary has histologically confirmed (World Health Organization (WHO) grade IV astrocytoma), newly diagnosed, supratentorial GBM; and,
2. The beneficiary has received initial treatment with maximal debulking surgery (when feasible), followed by chemotherapy and radiotherapy; and,
3. Tumor treatment field therapy is initiated within 7 weeks from the last dose of concomitant chemotherapy or radiotherapy, whichever is later; and,
4. The beneficiary has no evidence of progression by Response Assessment in Neuro-Oncology (RANO) criteria; and,
5. The beneficiary has a Karnofsky Performance Score (KPS) of at least 70; and,
6. The beneficiary will use TTFT for an average of 18 hours per day.
If all of the coverage criteria above are not met, claims for code E0766 will be denied as not reasonable and necessary.
CONTINUED COVERAGE FOR NEWLY DIAGNOSED GBM BEYOND THE FIRST THREE MONTHS OF THERAPY:
Continued coverage of TTFT (E0766) beyond the first three months of therapy requires that no sooner than the 60th day but no later than the 91st day after initiating therapy, the treating practitioner must conduct a clinical re-evaluation and document that the beneficiary is continuing to use and is benefiting from TTFT.
Documentation of clinical benefit is demonstrated by:
1. In-person clinical re-evaluation by the treating practitioner; and,
2. Objective evidence of adherence to therapy, reviewed by the treating practitioner.
You can find this rule at Local Coverage Determination (LCD): Tumor Treatment Field Therapy (TTFT) (L34823) (eff. 1/1/20).
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com.
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that MBBs are indicated for: 
 Patient must have a history of at least 3 months of moderate to severe pain with functional impairment 
and the pain is inadequately responsive to conservative care such as non-steroidal anti-inflammatory 
drugs (NSAIDs), acetaminophen and/or physical therapy (as tolerated). 
 The pain is predominantly axial and, with the possible exception of facet joint cysts, not associated with 
radiculopathy or neurogenic claudication.  
 There is no non-facet pathology that could explain the source of the patient?s pain, such as fracture, 
tumor, infection or significant deformity. 
 Clinical assessment implicates the facet joint as the putative source of pain. 
You can find this rule at Local Coverage Determination (LCD): Facet Joint Injections, Medial Branch Blocks, 
and Facet Joint Radiofrequency Neurotomy (L36471) (eff. 10/10/19). 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that Medicare pays only for ambulance transport. Ambulance vehicles must be designed and 
equipped to meet certain requirements. The vehicle must have emergency warning lights, sirens, 
communications equipment, a stretcher, linens, emergency medical supplies, oxygen equipment and other life-
saving equipment. The vehicle also must be staffed with two people, one of whom is certified as an emergency 
medical technician. Medicare will not pay for transport by vehicles that do not meet these requirements. You 
can find this rule at 42 CFR Section 410.41. 
 
The rules say that plans may offer a supplemental benefit to provide transport not covered by original 
Medicare. The transport offered must be used only for the enrollee's health care needs, such as transport to the 
doctor's office. The transport must be arranged or directly provided by the health plan. The transport may not 
be used for other than health-related purposes. You can find this rule in the Medicare Managed Care Manual, 
Chapter 4, Section 30.3. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The contract 
says that the Plan covers routine, non-ambulance transportation as a supplemental (extra) benefit. This benefit 
covers 14 one-way routine transportation trips are covered each calendar year. You can find this information on 
page 93 of the Plan's 2020 Evidence of Coverage.
Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules state that coverage and payment for Medicare telehealth services includes consultation, office visits, 
individual psychotherapy, and pharmacologic management delivered via a telecommunications system. 
Eligible geographic areas include rural health professional shortage areas (HPSA) and counties not classified as 
a metropolitan statistical area (MSA). The originating site for telehealth services (location to which the enrollee 
presents) must be a practitioner?s office, hospital, rural health clinic (RHC), federally qualified health center 
(FQHC), skilled nursing facility or community mental health center. You can find this rule in the Medicare 
Claims Processing Manual, Chapter 12, Sections 190.1 and 190.2. 
  
The rules say that for eligible telehealth services, telecommunications systems substitute for an in-person 
encounter. Medicare enrollees are eligible for telehealth services only if they are presented from an originating 
site located in either a county outside of a Metropolitan Statistical Area (MSA) or a rural Health Professional 
Shortage Area (HPSA) located in a rural census tract. You can find this in the CMS MLN document entitled 
Telehealth Services. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules state that the correct coding edit table contains edits which are pairs of HCPCS/CPT codes that in 
general should not be reported together.  Each edit has a column one and column two HCPCS/CPT code. If a 
provider reports the two codes of an edit pair, the column two code is denied, and the column one code is 
eligible for payment. You can find this rule in the National Correct Coding Initiative Policy Manual for 
Medicare Services, Chapter 1. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say a health plan must disclose to its enrollees in clear, accurate terms all cost-sharing information 
(such as copayments, deductibles and coinsurance). You can find this rule at 42 CFR Section 422.111(a) and 
(b). 
 
The rules say that a copayment is a fixed amount charged to an enrollee on a per-service basis. The rules say 
that coinsurance is a fixed percentage of the total amount paid for a health care service that can be charged to 
an enrollee on a per-service basis. You can find this rule at 42 CFR Section 422.2. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The Plan 
contract says that enrollees must pay a $90 copayment for emergency care. You can find this information on 
page 67 of the Plan's 2020 Evidence of Coverage (EOC).
Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that Medicare may cover medically accepted off-label uses for FDA-approved drugs used in an 
anti-cancer chemotherapeutic regimen. Medicare maintains a list of compendia which define if a use is 
medically accepted. The off-label use must be supported in one or more of these compendia or in published, 
peer-reviewed medical literature. 

An off-label use must be supported in one or more of the compendia and the use must not be listed as 
unsupported, not indicated, not recommended, or equivalent terms, in any of the compendia. An off-label use 
may also be determined by the carrier in the state to be reasonable and necessary. You can find these rules and 
the list of the Medicare-recognized compendia in the Medicare Benefit Policy Manual, Chapter 15, Section 
50.4.5. 
 
The rules say that white blood cell growth factors, also known as granulocyte colony stimulating factors (G-
CSF), are administered to enhance recovery of blood related functions in neutropenia (low white blood count) 
including febrile neutropenia (FN). G-CSF pegfilgrastim (Neulasta) and the biosimilar Fulphila are indicated 
for the following: 
 Patients with Cancer Receiving Myelosuppressive Chemotherapy: to decrease the incidence of infection, as 
manifested by FN, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs 
associated with a clinically significant incidence of severe febrile neutropenia. 
 Patients with Hematopoietic SubSyndrome of Acute Radiation Syndrome: to increase survival in patients 
acutely exposed to myelosuppressive doses of radiation 
 
Neulasta and biosimilars are not indicated for the mobilization of peripheral blood progenitor cells for 
hematopoietic stem cell transplantation. You can find this rule in the Local Coverage Determination for White 
Cell Colony Stimulating Factors, L37176 (eff 10/10/19). 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules state that comprehensive genomic profile (CGP) testing is not defined as a targeted panel by MolDX, 
and it is a test not currently satisfactorily described by any existing Current Procedural Terminology (CPT) 
code. Therefore, to report a CGP service, test providers should use CPT code 81479 for date of service 
February 12, 2020, in addition to the approved DEX Z-Code for the test. You can find this rule in Local 
Coverage Article (LCA) Billing and Coding: MolDX: Targeted and Comprehensive Genomic Profile Next-
Generation Sequencing Testing in Cancer (A55624). 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that plans may choose the networks of providers available to enrollees and may require enrollees 
to obtain authorization before receiving services. You can find this rule at 42 CFR Section 422.112(a) and in 
the Medicare Managed Care Manual, Chapter 1, Section 20.2. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The Plan 
contract says that, with limited exceptions, members of the Plan must use network providers to get medical care 
and services. The only exceptions are emergencies, urgently needed care when the network is not available 
(generally, when the enrollee is out of the area), out-of-area dialysis services, and cases in which the Plan 
authorizes the use of out-of-network providers. You can find this information on pages 27 to 32 of the Plan's 
2019 Evidence of coverage.
Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say a health plan must disclose to its enrollees in clear, accurate terms all cost-sharing information 
(such as copayments, deductibles and coinsurance). You can find this rule at 42 CFR Section 422.111(a) and 
(b). 
 
The rules say that a copayment is a fixed amount charged to an enrollee on a per-service basis. The rules say 
that coinsurance is a fixed percentage of the total amount paid for a health care service that can be charged to 
an enrollee on a per-service basis. You can find this rule at 42 CFR Section 422.2. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The Plan 
contract says that enrollees must pay a $345 copayment for surgery services at an in-network outpatient 
hospital. Unless the provider has written an order to admit you as an inpatient to the hospital, you are an 
outpatient and pay the cost-sharing amounts for outpatient hospital services. Even if you stay in the hospital 
overnight, you might still be considered an outpatient. If you are not sure if you are an outpatient, you should 
ask the hospital staff. You can find this information on pages 78 to 79 of the Plan's 2020 Evidence of Coverage 
(EOC).
Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules state that the following are indications of facet joint injections: 
 Patient must have history of at least 3 months of moderate to severe pain with functional impairment and 
pain is inadequately responsive to conservative care such as NSAIDs, acetaminophen, physical therapy (as 
tolerated). 
 Pain is predominantly axial and, with the possible exception of facet joint cysts, not associated with 
radiculopathy or neurogenic claudication. 
 There is no non-facet pathology that could explain the source of the patient's pain, such as fracture, tumor, 
infection, or significant deformity. 
 Clinical assessment implicates the facet joint as the putative source of pain. 
 
You can find these rules in the Local Coverage Determination (LCD) for Facet Joint Injections, Medial Branch 
Blocks, and Facet Joint Radiofrequency Neurotomy, L35936. This LCD is effective for services provided on or 
after December 5, 2019. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that Medicare may cover a drug or biological if it is safe and effective and otherwise reasonable 
and necessary. You can find this rule in the Medicare Benefit Policy Manual, Chapter 15, Section 50.4.1. 
  
Medicare rules also allow the plan to use step therapy. This is the process of beginning drug therapy for a 
medical condition with "preferred" (or more cost-effective) on-formulary drug alternative(s) and progressing to 
other drug therapies only as necessary. A plan must grant an exception to its step therapy rules if it determines 
that the requested drug is medically necessary, consistent with the prescriber's statement. The statement must 
show that the step therapy drugs: have been ineffective in treating the enrollee; or are likely to be ineffective or 
adversely affect the drug's effectiveness or patient compliance; or are likely to cause an adverse reaction or 
other harm to the enrollee.  
 
Medicare Advantage plans should ensure that new step therapy requirements do not disrupt ongoing Part B 
drug therapies for enrollees. Step therapy may only be applied to new prescriptions or administrations of Part B 
drugs for enrollees that are not actively receiving the affected medication. You can find this information at 42 
CFR Section 423.578(b)(5)(ii). 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The contract 
says that the Plan has step therapy requirements for certain Medicare Part B covered drugs/biologicals. 
Enrollees may be required to try a preferred drug before the Plan will approve the requested medication. The 
health plan contract says that Prolia is subject to step therapy. The member must meet the following criteria: 
has a history of osteoporotic fracture, or has tried or cannot use zoledronic acid (step therapy requirement). You 
can find this rule in the plan's Pharmacy and Therapeutics Prolia (denosumab) Coverage Policy.
Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules state that comprehensive genomic profile (CGP) testing is not defined as a targeted panel by MolDX, 
and it is a test not currently satisfactorily described by any existing Current Procedural Terminology (CPT) 
code. Therefore, to report a CGP service, test providers should use CPT code 81479 for date of service March 
4, 2020, in addition to the approved Dex Z-Code for the test. You can find this rule in Local Coverage Article 
(LCA) Billing and Coding: MolDX: Targeted and Comprehensive Genomic Profile Next-Generation 
Sequencing Testing in Cancer (A55624). 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say a health plan must disclose to its enrollees in clear, accurate terms all cost-sharing information 
(such as copayments, deductibles and coinsurance). You can find this rule at 42 CFR Section 422.111(a) and 
(b). 
 
The rules say that a copayment is a fixed amount charged to an enrollee on a per-service basis. The rules say 
that coinsurance is a fixed percentage of the total amount paid for a health care service that can be charged to 
an enrollee on a per-service basis. You can find this rule at 42 CFR Section 422.2. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The Plan 
contract says that enrollees must pay a $255 copayment for each covered surgery in an ambulatory surgical 
center. You can find this information on page 72 of the Plan's 2019 Evidence of Coverage (EOC).